Cargando…
Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China
BACKGROUND: Autologous stem cell transplantation (ASCT) has been recommended as a standard approach for young multiple myeloma (MM) patients for decades, even in the era of novel agents. Gain of chromosome 1q21 is a common cytogenetic abnormality in MM, while its clinical prognostic value is still c...
Autores principales: | Gao, Wen, Jian, Yuan, Du, Juan, Li, Xiaozhe, Zhou, Huixing, Zhang, Zhiyao, Yang, Guangzhong, Wang, Guorong, Tian, Ying, Li, Yanchen, Wu, Yin, Fu, Weijun, Li, Juan, Chen, Wenming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643680/ https://www.ncbi.nlm.nih.gov/pubmed/32881351 http://dx.doi.org/10.1002/cam4.3254 |
Ejemplares similares
-
Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era
por: Zhou, Huixing, et al.
Publicado: (2023) -
Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation
por: Geng, Chuanying, et al.
Publicado: (2022) -
What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk?
por: Gao, Wen, et al.
Publicado: (2020) -
Characteristics and Risk Factors of Ultra-High-Risk Patients with Newly Diagnosed Multiple Myeloma
por: Geng, Chuanying, et al.
Publicado: (2023) -
1q21 Gain Combined with High‐Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China
por: Li, Xiaozhe, et al.
Publicado: (2019)